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Disease and Other Dementias
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Abstract
Metabolic syndrome is a condition that includes several components which, 
individually and together, are steadily increasing in prevalence worldwide. These 
include obesity, dyslipidemia, hyperglycemia, and hypertension. On the other 
hand, Alzheimer’s disease, one of the family of dementias, is considered a disease 
of the elderly, whose numbers are also increasing. However, it has been found that 
the presence of the components of metabolic syndrome in earlier life, especially 
middle age, increases the risk of Alzheimer’s disease, although it has recently been 
suggested that these components may begin the progression to dementia as early as 
adolescence. The full pathophysiology of Alzheimer’s and the mechanisms by which 
metabolic syndrome affects it are not fully understood to date. The present chapter 
examines the association between metabolic syndrome and Alzheimer’s disease and 
the association between the components of metabolic syndrome and Alzheimer’s. 
The authors also represent the genetic involvement in this association, since various 
genes have been found to be common to both disorders.
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1. Introduction
Metabolic syndrome is a medical condition that includes obesity, dyslipidemia, 
hyperglycemia, and hypertension. It and its components have been recognized as an 
important risk factor for cardiovascular disease, both macrovascular and micro-
vascular. Given the worldwide epidemic in obesity and diabetes, this syndrome has 
received serious attention in recent years, although the condition has been studied 
since it was first described by G. Reaven in 1988 [1]. Metabolic syndrome has been 
linked to the risk of cardiovascular disease (CVD) and, more recently, to neuro-
degenerative diseases, including cognitive decline and dementia, which include 
Alzheimer’s disease (AD) [2–4]. The complex relation between metabolic syn-
drome and dementia is not well understood and remains elusive and controversial. 
Differences in age, definitions, and sample size have further obscured the truth.
Just what is Alzheimer’s disease? Alzheimer’s disease is considered a chronic 
neurodegenerative illness affecting the cerebral cortex and hippocampus that lasts 
8–10 years but which has a preclinical period of 20–30 years. AD is a growing health 
Advances in Dementia Research
2
concern, given the increase in elderly worldwide. Surprisingly, this disease can recede 
in individuals over 98 years of age [5]. Currently, it is estimated that 1 in 9 adults in 
US suffers from this disease, and that number is expected to grow by 40% by 2025 [6, 
7]. AD is characterized by two factors: neuron plaques made up of amyloid beta (Aβ) 
protein and phosphorylated tau protein, which forms altered structures and leads to 
intercellular neurofibrillary tangles. Amyloid-β oligomers have been shown to cause 
tau phosphorylation in vitro, which would lead to neurodegeneration. In addition, it 
has been suggested that amyloid-β also induces tau pathology in vivo [8]. This infers 
that the amyloid-β lesions precede the tau phosphorylation. Amyloid-β is found in 
the mitochondrial membrane. Abnormalities in amyloid-β cause an increase in the 
production of reactive oxygen species (ROS), leading to oxidative stress and lipid per-
oxidation in the neurons. This oxidative stress reduces levels of superoxide dismutase 
in the mitochondria. This alteration, in turn, leads to an increase in hyperphosphory-
lation of tau. RCAN1 is a protein produced in response to oxidative stress. If RCAN1 is 
chronically stimulated, may promote neurodegeneration [9].
The pathology of Alzheimer’s disease, and various other dementias, includes loss 
of neuronal connections in the hippocampus and temporal lobes, neurofibrillary 
tangles (NFTs), amyloid-β (Aβ), and amyloidopathy of the cerebrovasculature [10].
While the exact mechanisms are still not entirely clear, it has been noted that 
other conditions usually accompany AD, such as cardiovascular disease and meta-
bolic syndrome. In addition, Alzheimer’s usually includes various important comor-
bidities, including white matter lesions; brain hypoperfusion, usually undetected 
microinfarcts; and cardiovascular dysfunction. Other comorbidities include obesity, 
diabetes, and hypertension, collectively known as metabolic syndrome [11, 12].
However, the definitions of Alzheimer’s disease and other forms of dementia are 
slowly becoming blurred, which may suggest that dementia, and Alzheimer’s disease 
in particular, is the result of a series of various pathologies which all converge [13]. 
Results from the Nun Study and Honolulu-Asia Aging Study indicate that a complex 
set of cerebral alterations determines the progression of clinically diagnosed AD 
[14]. The complete mechanisms for the progression of dementia are not yet known. 
Neither is how the components of metabolic syndrome individually and collectively 
trigger cognitive decline. However, research is currently focusing on various aspects 
of this association, in order to design better strategies to combat both conditions.
In addition, various genetic factors have been uncovered which are common to 
both diseases, suggesting an association [15].
The present chapter will look at the effect of the metabolic syndrome, and each 
of its components, on the presence and progression of Alzheimer’s disease and 
other related dementias. It will also look at the genetic factors which have been sug-
gested as being associated, as they are common to both conditions. The authors will 
briefly review the association of age to the progression to Alzheimer’s disease.
2. Metabolic syndrome and Alzheimer’s disease
The twenty-first century has seen a surge of interest in the association between 
metabolic syndrome and dementia, specifically, Alzheimer’s disease. Given the 
epidemic of metabolic syndrome and its components (obesity, diabetes, hyperten-
sion) worldwide, and the fact that populations are living longer and therefore more 
prone to age-related diseases, this is not surprising. There is mounting evidence 
that the presence of metabolic syndrome, or of its components, increases the risk 
of AD. Although the exact physiopathology of AD is not completely understood, 
various studies have discovered links between these two conditions.
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In the North Manhattan study, each of the components of metabolic syndrome 
was measured for the risk of dementia. Elevated levels of pro-inflammatory 
cytokines, including tumor necrosis factor (TNF) was associated with the risk 
of dementia, as were HDL-cholesterol and the presence of diabetes, although in 
univariate analysis high blood pressure also associated. This study suggested that 
metabolic syndrome be considered as a risk factor as a whole, even when the indi-
vidual components did not significantly increase the risk [16]. Various studies have 
stated that the greater the number of components of metabolic syndrome present, 
the greater the risk of dementia [16, 17].
Some studies have found that metabolic syndrome is a risk factor for dementia 
up to a certain age (reports vary from 65 to 80 years as the cutoff point), and then it 
becomes a protector. However, Fan et al. found that the onset of metabolic syn-
drome increased the risk of dementia irregardless of the age at onset, meaning that 
the onset of metabolic syndrome even beyond these cutoff points poses a risk of 
Alzheimer’s disease [18].
Another possible explanation for this enigma was presented by Watts et al., 
who believe that the relationship between metabolic syndrome and dementia is not 
linear. They believe that while the metabolic biomarkers at midlife signal the onset 
of Alzheimer’s disease, in the elderly, they are signs and symptoms rather than 
causes. However, they point out that by then the prolonged effects of metabolic syn-
drome have already progressed over decades and the systems involved in cognitive 
function have been altered [19]. Bowler et al. note that, in addition, the elderly are 
frequently in poor health, including malnutrition, which may mask or overpower 
the effect of metabolic syndrome [20].
At the same time, a study among Chinese population with mild cognitive 
impairment found that the presence of three or more components of metabolic 
syndrome increased the risk of Alzheimer’s disease four times and twice as great 
just with the presence of diabetes [21]. Likewise, a study with Italian population 
found that the presence of metabolic syndrome in patients with mild cognitive 
impairment was a predictor of Alzheimer’s disease over the 3.5 years of follow-up 
in their study. They also noted that among the components of metabolic syndrome, 
hypertriglyceridemia, abdominal obesity, and hypertension were the most predic-
tive of progression to AD [22].
2.1 Obesity and dementia
Obesity has become a worldwide epidemic in recent years. Hand in hand with 
this growth, attention has turned to the relation between obesity, as measured by 
body mass index (BMI), and dementia, specifically Alzheimer’s disease. Since this 
is one of the factors of AD that can be controlled, it is important to consider in the 
timely prevention of progression to dementia.
Obesity impacts dementia not only by limiting blood supply to the brain but 
also by increasing the number of fat cells, which restricts the white matter of the 
brain and causes cognitive decline. To put this in perspective, the average human 
has a total of 5 l of blood. More fat translates into less blood supply for the brain, 
causing ischemia [23]. In addition, obesity entails a higher concentration of adipo-
kines (fat cells from cytokines). These decrease the brain’s white matter, resulting 
in decreased neuronal connections and brain atrophy. Therefore, obesity as early 
as adolescence has vascular repercussions later in life, mostly due to the continued 
inflammation and adipose-related hormone levels [23]. In fact, the presence of 
obesity in middle age increases the risk for AD in later years twofold, more than 
hypertension or high cholesterol [24].
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Finally, the underlying causes of obesity, such as a diet high in fats and sugars, 
influence gut microbiota and disrupt the so-called gut-brain axis, resulting in 
inflammation that ends in neurodegeneration and, again, brain atrophy [23].
Fibroblast growth factor 21 (FGF21) is a hormone that plays an important role in 
metabolic regulation and has a positive correlation with BMI and obesity. However, 
in the presence of neuronal dysfunction, FGF21 is released, reducing the damage 
caused by the neuronal activity. This mechanism is complicated by obesity, which 
effectively blocks the FGF21 activity, permitting cognitive decline [25].
At a more direct level, obesity causes cerebral hypoperfusion, which increases 
β-amyloid production which, in turn, causes endothelial dysfunction, terminat-
ing in a dangerous cycle that results in the pathogenic changes found in dementia. 
This occurs due to a rise in levels of asymmetric dimethylarginine, which decreases 
nitrous oxide, causing oxidative stress. Various studies have shown that dysfunc-
tion of the brain mitochondria increases pro-apoptotic proteins (bax and bad) and 
decreases anti-apoptotic protein (Bcl-2), resulting in brain apoptosis [26].
Increased fat mass and obesity-associated protein (FTO) are responsible for the 
prefrontal cortex’s processing of food stimuli (sight, smell, taste). If FTO is overex-
pressed, it leads to an increase in food consumption, resulting in obesity. FTO has 
also been shown to trigger the phosphorylation of tau in the neurons [27].
Given the fact that obesity is a controllable condition, this should be a focus in 
the prevention of AD and dementia. It should also be remembered that weight loss 
programs also reduce other risk factors for AD involved in metabolic syndrome, 
such as dyslipidemia and hypertension. Figure 1 shows the possible link between 
obesity and dementia.
2.2 Dyslipidemia and dementia
It has been suggested that high low-density cholesterol (LDL-c) and low high-
density cholesterol (HDL-c) as early as midlife contribute to the development of 
AD later in life. One study found that high total cholesterol (>240 mg/dL) as early 
Figure 1. 
Possible link between obesity and dementia. Some studies suggest that several factors associated with obesity are 
also associated with the development of Alzheimer’s disease.
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as in one’s 30s carries a 57% higher risk of developing AD 30 years later [28]. Low 
LDL-c early in life associates with Aβ plaques later on, a biomarker of AD [29]. This 
has been proven to be true even in individuals as young as 40 years old [30].
Excess lipids can trigger an increased production of Aβ, leading to the 
development of plaques. These lipids may also lead to insulin resistance, which 
will be discussed later on. In addition to the cholesterol, serum triglycerides 
are a vital factor in this process. Hypertriglyceridemia has been shown to affect 
brain processes, by altering the peptides crossing the blood-brain barrier, such 
as decreasing leptin bioavailability. Other affected peptides include galanin 
(GAL), the opioid peptides enkephalin (ENK) and dynorphin (DYN), and the 
orexins (ORX) [31]. One study in mice found that by lowering triglycerides, 
especially triolein, cognitive damage could actually be reversed [32]. The 
metabolism of cholesterol and lipid proteins in the central nervous system 
occurs independently from the peripheral nervous system. Processed choles-
terol can cross the blood-brain barrier and bind to either LDL-c or HDL-c. 
These lipids, especially cholesterol, have a key function in the physiopathology 
of AD. We have seen, and will discuss further, that high cholesterol in middle 
age increases the risk of AD in later life. However, high levels of cholesterol 
later in life actually reduces the risk of AD [33].
While exact mechanisms remain elusive, it is very possible that the inflamma-
tion that accompanies dyslipidemia is at the root of this association and holds a 
key role in the pathogenesis of dementia. It should be noted that there are genetic 
implications, which will be discussed later on. It has been found that mononuclear 
cells of elderly AD patients have high levels of inflammatory cytokines, such as 
IL-1β, IL-6, IL-12, IL-16, and IL-18 and tissue growth factor (TGF)-β1. It has been 
found that these inflammation cytokines, as well as anti-inflammatory IL-10 and 
IL-13, are found in increased concentrations in the brains of AD patients [34].
In AD, Aβ reaction with microglial receptors can lead to a highly inflamed 
state [35]. It appears that the activation of the microglial cells unleashes the pro-
inflammatory cytokines, leading to increased Aβ and tau hyperphosphorylation. In 
addition, IL-1β can cause the production of inflammatory factors and has shown to 
play a variety of roles in neuron damage.
It is widely accepted that obesity incurs systemic inflammation. 
Hypercholesterolemia is known to increase the levels of inflammatory cytokines. 
Neuroinflammation and neurodegeneration increase microglial activation. This 
leads to a further inflamed state, resulting in a vicious cycle. However, lifestyle 
changes that lower LDL-c and triglycerides and raise HDL-c can help prevent or 
possibly reverse the cognitive damage.
2.3 Diabetes and dementia
One of the most widespread outcomes of metabolic syndrome is diabetes 
mellitus. Both type 2 diabetes mellitus (T2DM) and dementia are considered age-
related diseases, although, as we will see later on, this assumption may need to be 
changed. While the full impact of diabetes on cognitive decline and dementia is still 
not completely known, alterations in cognition begin as early as pre-diabetes [36]. 
Various domains of the brain have been shown to be affected by T2DM, suggesting 
that the diabetes negatively impacts the processing networks [37]. However, diabe-
tes has not been directly linked to the neuropathology of dementia. Nevertheless, 
there are other means by which diabetes may be closely linked to dementia, espe-
cially Alzheimer’s disease. One of these links may lie in the fact that T2DM usually 
leads to atherosclerosis, which mediates cognitive decline. Another may lie in the 
alterations to cerebral glucose metabolism, as suggested by Chornenkyy et al. 
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[38]. Evidence from studies such as the Baltimore Longitudinal Study of Aging 
have shown, through autopsy, that glucose metabolism is altered in the orbital and 
prefrontal cortex, temporal cortex (middle gyrus, parahippocampal gyrus, and 
uncus), and cerebellar regions in cases of Alzheimer’s disease [39, 40]. It is possible 
that there is an upstream effect and that these alterations in glucose metabolism 
impact the β-amyloid deposition, a characteristic of AD. In addition, these altera-
tions in glucose metabolism would affect the mitochondria, causing them to release 
reactive oxygen species (ROS) and triggering apoptosis. The increased ROS, in turn, 
accelerates the metabolic syndrome while at the same time impacting β-amyloid 
processing.
Another means by which T2DM may affect AD lies in lipid metabolism. 
Cholesterol affects the peptide levels in β-amyloids. Increases in cholesterol cause 
increases in the levels of cholesteryl esters, which in turn increase β-amyloid 
concentrations [41].
Insulin resistance (IR) is one of the main characteristics of T2DM. Research 
has increasingly found that IR is a factor in dementia. Much attention is being paid 
to the inflammatory markers associated with IR, such as interleukin-6 (IL-6) and 
C-reactive protein (CRP). In fact, Singh-Manoux et al. found that increased IL-6 as 
early as middle age is a predictor of dementia later in life [42]. It has been suggested 
that these inflammatory cytokines cause thrombotic vascular events, which then 
lead to cerebral infarction. Another way in which IR may affect dementia is related 
to the higher cortisol levels found in T2DM, which have long been linked to cogni-
tive decline and dementia.
Finally, one of the common complications of T2DM is diabetic autonomic 
neuropathy (DAN). It has been suggested that the presence of DAN signals altera-
tions in the hypothalamus, midbrain, brainstem and cortex. One study found that 
treatment with plasmapheresis improved performance on cognitive tests, indicating 
improvement in autonomic nephropathy [43].
2.4 Hypertension and dementia
Hypertension has been identified as a risk factor for cognitive decline. In fact, 
various studies have associated midlife hypertension with dementia later in life  
[44, 45].
Left ventricular hypertrophy (LVH) is usually an end result of hypertension.  
A very recent study has associated the presence of LVH in midlife with the inci-
dence of dementia [46].
It is known that unchecked hypertension leads to microinfarcts and microhe-
morrhages, which in turn inhibit cognitive function. Hypertension also induces an 
increase in Aβ peptides in the brain while inhibiting vascular clearance of amyloids 
[47]. The ensuing accumulation results in amyloid angiopathy, a classic indica-
tor of AD. In addition, these microinfarcts and microhemorrhages cause white 
matter lesions. A study in 2004 found that patients with hypertension and the 
resulting white matter lesions did significantly poorer on neurological tests [48]. 
Unfortunately, this study did not include adequate follow-up to track progression to 
dementia and Alzheimer’s disease.
One important recent study concentrated not on amyloid activity but rather 
on tau phosphorylation. Raz et al. [49] found that the vascular alterations caused 
by hypertension promoted tau phosphorylation, leading to cell death and brain 
atrophy. They explain that chronic hypertension alters the arterial endothelial cell 
lining, causing hypoxia and changing oxidative metabolism. This in turn triggers 
an inflammatory cascade that ends in neuronal cell death. The hypoxic hypoperfu-
sion also triggers a neuropathological cycle, which involves the production of free 
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radicals, activation of microglias, alteration of the blood-brain barrier, and tau 
hyperphosphorylation.
Several studies have found that the use of antihypertensive drugs, especially 
diuretics, can reduce the risk of Alzheimer’s disease. These studies include the 
Ginkgo Evaluation of Memory study (GEM) [50] and the Cache County study, a 
hallmark of study in this area [51, 52]. More research is needed to see if the use of 
antihypertensive medication and/or diuretics is a therapeutic option for those with 
a high risk of Alzheimer’s.
3. Genetics, metabolic syndrome, and dementia
With the development of genome-wide association studies (GWAS), more 
information about the association between metabolic syndrome and dementia has 
become available. By comparing the phenotypes associated with cardiovascular 
disease and metabolic syndrome with those most common to Alzheimer’s disease, 
researchers have been able to establish common links, and with that information 
establish the genetic risk factors for metabolic syndrome that also confer risk of 
Alzheimer’s disease [53].
Apolipoprotein E (ApoE) is the major cholesterol transporter in the brain. With 
the discovery of the ApoE4 allele, a key to the pathogenesis of AD was uncovered. It 
was found that the presence of this allele associates with the risk of developing AD 
at a younger age, especially in the presence of ApoE4/E4 homozygotes [54].
However, ApoE2/E3 has a protector effect. In addition, some ApoE4- haplotypes 
enable the protector effect of lipids on neural membranes, while ApoE4+ impairs 
this effect [55]. This may help at least to partially explain the difficulty in assigning 
the role of lipids in AD. Nevertheless, single nucleotide polymorphisms (SNPs) 
of ApoE have been identified as being related with lipid metabolism (CLU and 
ABCA7) and with inflammation (CR1 and HLADRB5) [56, 57]. Nevertheless, this 
situation may not be a permanent one. A case study published by Brown et al. inter-
vened in the case of a 38-year-old man with metabolic syndrome and mild cognitive 
decline, who came from a family with a background of Alzheimer’s disease. He 
was put on a ketogenic diet and given a program of high-intensity exercise. After 
10 weeks, the biomarkers of the metabolic syndrome improved, as did his memory 
function. Insulin signaling approached normal, indicating that the ApoE4 gene had 
been effectively silenced [58].
These are not the only genetic markers. A rare variant in TREM-2 shares in 
the risk of AD [59, 60]. Reduce of the biomarkers of metabolic syndrome showed 
marked improvement, and his memory improved; expression of SORL1 also leads 
to Aβ accumulation. In addition, the interaction between SORL1 and ApoE closely 
associates with an increased risk of AD [61]. Another candidate is sirtuin 1 (SIRT1). 
It has been suggested that the protein of this gene, together with PGC1α, may help 
maintain brain function by participating in the regulation of mitochondrial func-
tion. This, in turn, activates the endothelial growth factor (VEGF) and conserves 
the integrity of the blood-brain barrier. At the same time, the aging process in itself 
promotes reactive oxygen species (ROS), which accumulated and caused mitochon-
drial dysfunction, lowering VEGF and leading to Aβ deposits, which form plaques 
and cause Alzheimer’s disease [62].
In addition, Zhang et al. recently compared the genetic markers of metabolic 
syndrome, dementia, and diabetes and found 86 genes common to all 3 diseases, 
which if combined comprised 43% of the genes known to be associated with 
dementia, including APOE, APP, PARK2, CEPBP, PARP1, MT-CO2, CXCR4, IGFIR, 
CCR5, and PIK3CD [63].
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Other, less frequent genetic risk factors include phosphatidylinositol binding 
clathrin assembly protein (PICALM), CD33, triggering receptor expressed on 
myeloid cells 2 (TREM2), the ATP binding cassette transporter ABCA7, clusterin 
(CLU) and complement receptor type 1 (CR1), all of which are suspected as being 
involved in the clearance pathways of Aβ [5].
Another important link between metabolic syndromes may lie in microRNA. These 
tiny RNAs have been accepted as being involved in metabolic syndrome but have also 
recently been found consistently in Alzheimer’s patients. These include hsa-mir-21 
(obesity, hypertension, and T2DM), hsa-mir-103ª (hypertension and diabetes), hsa-
mir-17 (hypertension and obesity), hsa-mir-107 (obesity and T2DM), and hsa-mir-
20ª (hypertension). Again, this factor is modifiable with improved metabolic control, 
and the risk of dementia can be delayed or even eliminated [64].
4. Aging and dementia
Dementia and especially Alzheimer’s disease are more prevalent in aged popula-
tion. However, not all patients are elderly. In addition, metabolic syndrome as early 
as adolescence can lead to early or elderly dementia.
One study, conducted on obese New York City minority (Hispanic, African-
American) adolescents (average age 16) with and without metabolic syndrome, 
found that those with metabolic syndrome already showed reduced executive func-
tion and cognitive flexibility [65]. The authors suggest that even short-term meta-
bolic alterations at that age would lead to neurological complications. Considering 
that at that age, white frontal matter is still in a developmental stage, these altera-
tions will have serious effects in later life, leading to early development of dementia 
and Alzheimer’ disease. Another study comparing healthy, obese, and type 2 
diabetes adolescents found that both obese and diabetic adolescents (12–18 years) 
had reduction and alterations in both gray and white matter in the brain. Gray mat-
ter volumes in the right hippocampus were reduced in the obese and then diabetic 
groups [66]. Given these facts, and especially considering the current worldwide 
epidemics in both obesity and diabetes, interventions need to be initiated very early 
to avoid the heavy burden of dementia later in life.
It has also been noted that metabolic syndrome in early to middle adulthood 
causes a high risk of later dementia. Rosanna Tortelli et al. examined the cognitive 
status of Italian population compared with their metabolic status in a study con-
ducted in 1985. They found that those with insulin resistance or diabetes in 1985 had 
an increased risk of suffering dementia 20 years later [67]. Chronic metabolic altera-
tions have cardiovascular and believed to be cerebrovascular effects. These include 
damage to the small vessels in the brain. This leads to white matter damage (including 
amyloid lesions) and subsequently to dementia. However, it is interesting to note 
that metabolic syndrome increases the risk of dementia in patients <80 years old, but 
not older [68, 69]. Another published study, which followed women with metabolic 
syndrome for 12 years, found that metabolic syndrome increased the risk of dementia 
almost 2.5 times (OR = 2.47) [70]. Nevertheless, a review of the literature found 
inconclusive results, possibly due to the variety of definitions, criteria, and testing 
methods [71]. However, it has been suggested that the events related to metabolic 
syndrome that are manifested during middle age can develop independent pathways 
as time progresses, causing the appearance of diagnosable dementia later in life [10].
A study by Phrommintikul et al. [72] compared the factors associated with 
cognitive decline between younger (<65 years old) and elderly (≥65 years) 
patients with metabolic syndrome. They found that in the younger patients, 
most of the components of metabolic syndrome, in addition to fibroblast 
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growth factor 21 (FGF21), were important factors in cognitive decline. 
However, in the elderly patients, only BMI was a significant factor, indicating 
that the association between metabolic syndrome and dementia may also be age 
dependent. Nevertheless, the elderly may also have already suffered damage 
from the long-term effects of metabolic syndrome. The reasons for this age-
dependent difference in the influence of metabolic syndrome remain unknown. 
On the other hand, a study of elderly Koreans found that metabolic syndrome 
and vitamin D deficiency were significant risk factors for dementia, increasing 
the risk threefold. This may be due to the fact that sufficient vitamin D has an 
anti-inflammatory and therefore protector effect [73]. Other studies exist, but 
the age cutoff has varied from 65 to 85 years. In all studies, nevertheless, those 
below the age cutoff showed an association between metabolic syndrome and 
Alzheimer’s, while it had an inverse association in those over the cutoff point 
used [74]. This fact may also help explain the controversial results reported 
when trying to associate metabolic syndrome with dementia.
The genes implicated in obesity and metabolic syndrome increased the risk of 
developing AD in late life (Table 1).
5. Future and emerging trends
The presence of metabolic syndrome in early and middle adulthood is an 
important risk factor for developing Alzheimer’s disease, as well as various other 
dementias. Physician’s need to be aware of the importance of the presence of these 
components, not only as risk factors for dementia but also for their significant risk 
of cardiovascular disease. However, the various components of metabolic syndrome 
are each modifiable with changes in behavior and lifestyle. Physical activity and 
weight control are becoming points of emphasis in the attempt to prevent the 
progression of these diseases, as well as cardiovascular disease and all-cause and 
cardiovascular mortality.
In addition, some pharmacological treatments have been suggested for meta-
bolic control and subsequent prevention of cardiovascular and dementia com-
plications. These include anti-glucemiant medications, such as metformin, and 
antihypertensive and anti-inflammatory drugs, such as diuretics and nondihydro-
pyridine calcium channel blocker.
Another emerging strategy involves the genetic risk of dementia. Research is 
searching for the genetic links between metabolic syndrome and dementia. Those 
with such genetic backgrounds should be monitored closely.
Gene 
symbol
Location Function References
ApoE 19q13.2 The major cholesterol carrier in the brain [54, 75]
CLU 8p21-p12 Important role in lipid transport in the brain [76, 77]
ABCA 9p13.3 Regulate cholesterol homeostasis and transport of high-
density lipoprotein cholesterol
[78, 79]
SOTL 9p13.3 Plays a key role in lipid metabolism and Aβ production [80, 81]
CRI 1q32 Multifunctional mediator of innate immunity involved in 
amyloid (Aβ) clearance from brain
[82, 83]
PICALM 11q14 Regulator of brain Aβ production [84]
Table 1. 
Genes implicated in risk of metabolic syndrome and dementia.
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Finally, the mechanisms of dementia are still not entirely understood. 
Researchers are trying to unravel the mystery of the brain and its complex relation-
ships, in order to better understand the best strategies to lower the prevalence of 
cardiovascular disease and to prevent the heartbreaking progression of dementia 
and especially of Alzheimer’s disease.
6. Conclusion
In conclusion, it appears clear that the metabolic syndrome and its components 
increase the risk of developing Alzheimer’s disease later in life. Most of these com-
ponents are modifiable. In addition to the pharmacological treatments, such as the 
use of diuretics, lifestyle modifications can probably decrease the damage leading to 
Alzheimer’s disease, as well as improving the quality of life of an increasingly older pop-
ulation. An added benefit would be the improvement in cardiovascular condition and 
the prevention and/or treatment of cardiovascular disease and cardiovascular mortality. 
Further research is needed to pursue three different avenues: (1) pathophysiology of the 
metabolic syndrome and dementia; (2) lifestyle interventions for the metabolic syn-
drome and their effect on the progression of dementia; and (3) the genetic link between 
the metabolic syndrome, AD, dementia progression, and cardiovascular disease.
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